F Leung1, A Dimitromanolakis, H Kobayashi, E P Diamandis, V Kulasingam. 1. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
Abstract
OBJECTIVES: Ovarian cancer is the most lethal gynecological malignancy in North America. Although survival rates are high when the disease is diagnosed at an early stage, this decreases exponentially in late-stage diagnoses. As such, there is a need for novel early detection biomarkers. Through an integrated approach to ovarian cancer biomarker discovery that combines proteomics with transcriptomics and bioinformatics, our laboratory has identified folate-receptor 1 (FOLR1) and Dickkopf-related protein 3 (Dkk-3) as putative biomarkers. The objective of this study was to measure the levels of FOLR1 and Dkk-3 in the serum of patients with ovarian cancer, benign gynecological conditions and healthy women. DESIGN AND METHODS: FOLR1 and Dkk-3 were analyzed in serum of 100 ovarian cancer patients, 100 patients with benign gynecological conditions, and 100 healthy women using enzyme-linked immunosorbent assays (ELISAs). All specimens were analyzed in triplicate. RESULTS: FOLR1 was significantly elevated in the serum of ovarian cancer patients compared to serum of both healthy controls (P<0.0001) and patients with benign gynecological conditions (P<0.0001). Furthermore, FOLR1 was strongly correlated with CA125 as both were elevated in the serous histotype and in late-stage disease. FOLR1 did not outperform CA125 in receiver operating characteristic curve analysis and there was no significant complementarity between the two markers. Dkk-3 was not significantly different between the three serum cohorts and was not correlated with CA125. CONCLUSIONS: FOLR1 is a new biomarker for ovarian cancer which correlates closely with CA125. The role of FOLR1 in the pathogenesis of ovarian cancer warrants further investigation.
OBJECTIVES:Ovarian cancer is the most lethal gynecological malignancy in North America. Although survival rates are high when the disease is diagnosed at an early stage, this decreases exponentially in late-stage diagnoses. As such, there is a need for novel early detection biomarkers. Through an integrated approach to ovarian cancer biomarker discovery that combines proteomics with transcriptomics and bioinformatics, our laboratory has identified folate-receptor 1 (FOLR1) and Dickkopf-related protein 3 (Dkk-3) as putative biomarkers. The objective of this study was to measure the levels of FOLR1 and Dkk-3 in the serum of patients with ovarian cancer, benign gynecological conditions and healthy women. DESIGN AND METHODS: FOLR1 and Dkk-3 were analyzed in serum of 100 ovarian cancerpatients, 100 patients with benign gynecological conditions, and 100 healthy women using enzyme-linked immunosorbent assays (ELISAs). All specimens were analyzed in triplicate. RESULTS:FOLR1 was significantly elevated in the serum of ovarian cancerpatients compared to serum of both healthy controls (P<0.0001) and patients with benign gynecological conditions (P<0.0001). Furthermore, FOLR1 was strongly correlated with CA125 as both were elevated in the serous histotype and in late-stage disease. FOLR1 did not outperform CA125 in receiver operating characteristic curve analysis and there was no significant complementarity between the two markers. Dkk-3 was not significantly different between the three serum cohorts and was not correlated with CA125. CONCLUSIONS:FOLR1 is a new biomarker for ovarian cancer which correlates closely with CA125. The role of FOLR1 in the pathogenesis of ovarian cancer warrants further investigation.
Authors: V E Krupnik; J D Sharp; C Jiang; K Robison; T W Chickering; L Amaravadi; D E Brown; D Guyot; G Mays; K Leiby; B Chang; T Duong; A D Goodearl; D P Gearing; S Y Sokol; S A McCarthy Journal: Gene Date: 1999-10-01 Impact factor: 3.688
Authors: Gooitzen M van Dam; George Themelis; Lucia M A Crane; Niels J Harlaar; Rick G Pleijhuis; Wendy Kelder; Athanasios Sarantopoulos; Johannes S de Jong; Henriette J G Arts; Ate G J van der Zee; Joost Bart; Philip S Low; Vasilis Ntziachristos Journal: Nat Med Date: 2011-09-18 Impact factor: 53.440
Authors: T Tsuji; I Nozaki; M Miyazaki; M Sakaguchi; H Pu; Y Hamazaki; O Iijima; M Namba Journal: Biochem Biophys Res Commun Date: 2001-11-23 Impact factor: 3.575
Authors: Alexander Liede; Beth Y Karlan; Rae Lynn Baldwin; Lawrence D Platt; Graciela Kuperstein; Steven A Narod Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Kristin L M Boylan; Ashley Petersen; Timothy K Starr; Xuan Pu; Melissa A Geller; Robert C Bast; Karen H Lu; Ugo Cavallaro; Denise C Connolly; Kevin M Elias; Daniel W Cramer; Tanja Pejovic; Amy P N Skubitz Journal: Cancers (Basel) Date: 2022-06-23 Impact factor: 6.575
Authors: Felix Leung; Marcus Q Bernardini; Marshall D Brown; Yingye Zheng; Rafael Molina; Robert C Bast; Gerard Davis; Stefano Serra; Eleftherios P Diamandis; Vathany Kulasingam Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-07-22 Impact factor: 4.254
Authors: Martin C Boonstra; Susanna W L de Geus; Hendrica A J M Prevoo; Lukas J A C Hawinkels; Cornelis J H van de Velde; Peter J K Kuppen; Alexander L Vahrmeijer; Cornelis F M Sier Journal: Biomark Cancer Date: 2016-09-27
Authors: Mary J Higgins; Antonio Serrano; Kofi Y Boateng; Victoria A Parsons; Tiffany Phuong; Alyssa Seifert; Jacob M Ricca; Kyle C Tucker; Alec S Eidelman; Maureen A Carey; Robert A Kurt Journal: Breast Cancer (Auckl) Date: 2016-10-27
Authors: Elisabeth Smolle; Valentin Taucher; Martin Pichler; Edgar Petru; Sigurd Lax; Johannes Haybaeck Journal: Int J Mol Sci Date: 2013-05-02 Impact factor: 5.923
Authors: Linda E Kelemen; James D Brenton; Christine Parkinson; Hayley C Whitaker; Anna M Piskorz; Ilona Csizmadi; Paula J Robson Journal: PLoS One Date: 2014-05-08 Impact factor: 3.240